CD16+ macrophages: an emerging biomarker for combined CTLA-4 and PD-1 blockade.
James W SmithyJason John LukePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In a retrospective analysis of patients with unresectable melanoma, higher pre-treatment tissue densities of CD16+ macrophages were associated with clinical benefit from combined CTLA-4 and PD-1 blockade. With further validation, this biomarker could serve as a tool in selecting between immune checkpoint inhibitor (ICI) regimens.